Company news

Avita Medical, Inc. news in 2022

Avita Medical, Inc.'s news releases, calls and decks from 2022, newest first.

View company

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

December 18, 2022

AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair

December 11, 2022

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

December 11, 2022

AVITA Medical Reports Third Quarter 2022 Financial Results

November 9, 2022

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

November 8, 2022

AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System

November 2, 2022

AVITA Medical to Announce Third Quarter 2022 Financial Results

October 19, 2022

AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer

September 27, 2022

AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System

September 11, 2022

RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns

August 31, 2022

AVITA Medical Reports Second Quarter 2022 Financial Results

August 10, 2022

AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System

August 10, 2022

AVITA Medical to Announce Second Quarter 2022 Financial Results

July 24, 2022

AVITA Medical Reports First Quarter 2022 Financial Results

May 11, 2022

AVITA Medical to Announce First Quarter 2022 Financial Results

April 27, 2022

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

April 20, 2022

AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction

March 20, 2022

Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.

March 1, 2022

AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results

February 27, 2022

The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company

February 22, 2022

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

February 16, 2022

AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021

January 9, 2022

AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction

January 5, 2022

Calls in 2022

Decks in 2022